NeoPharm was granted orphan drug designation by the FDA for its drug candidate, IL 13-PE (also known as IL13-PE38QQR) for the treatment of idiopathic pulmonary fibrosis (IPF).  Studies of IL 13-PE in animals and in ex vivo human tissue demonstrated promising results.

IL 13-PE is a recombinant protein that demonstrated selective cytotoxicity to IL13 receptor-expressing fibroblasts.  

For more information call (847) 887-0800 or visit www.neopharm.com.